ALVR Logo

AlloVir, Inc. (ALVR) 

NASDAQ
Market Cap
$65.82M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
425 of 774
Rank in Industry
222 of 432

Largest Insider Buys in Sector

ALVR Stock Price History Chart

ALVR Stock Performance

About AlloVir, Inc.

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, …

Insider Activity of AlloVir, Inc.

Over the last 12 months, insiders at AlloVir, Inc. have bought $0 and sold $214,047 worth of AlloVir, Inc. stock.

On average, over the past 5 years, insiders at AlloVir, Inc. have bought $36.7M and sold $13.14M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 2,930,870 shares for transaction amount of $10.99M was made by GILEAD SCIENCES, INC. (10 percent owner) on 2023‑06‑27.

List of Insider Buy and Sell Transactions, AlloVir, Inc.

2024-11-19SaleSee Remarks
3,186
0.0026%
$0.55$1,748+4.69%
2024-11-19SaleChief Executive Officer
8,706
0.0072%
$0.55$4,775+4.69%
2024-11-19SaleGeneral Counsel
432
0.0004%
$0.55$237+4.69%
2024-11-19SaleChief Accounting Officer
554
0.0005%
$0.55$304+4.69%
2024-11-05SaleSee Remarks
5,136
0.0044%
$0.86$4,442+14.48%
2024-11-05SaleChief Executive Officer
10,609
0.0091%
$0.86$9,176+14.48%
2024-11-05SaleGeneral Counsel
2,272
0.002%
$0.86$1,965+14.48%
2024-11-05SaleChief Accounting Officer
1,655
0.0014%
$0.86$1,431+14.48%
2024-10-22SaleSee Remarks
1,882
0.0016%
$0.77$1,4450.00%
2024-10-22SaleGeneral Counsel
766
0.0007%
$0.77$5880.00%
2024-10-22SaleChief Accounting Officer
486
0.0004%
$0.77$3730.00%
2024-10-21SaleSee Remarks
1,546
0.0013%
$0.78$1,204+14.32%
2024-10-21SaleChief Executive Officer
9,752
0.0085%
$0.78$7,597+14.32%
2024-10-21SaleGeneral Counsel
635
0.0006%
$0.78$495+14.32%
2024-10-21SaleChief Accounting Officer
479
0.0004%
$0.78$373+14.32%
2024-10-03SaleSee Remarks
940
0.0008%
$0.81$766-2.25%
2024-10-03SaleChief Executive Officer
1,493
0.0013%
$0.81$1,217-2.25%
2024-10-03SaleGeneral Counsel
377
0.0003%
$0.81$307-2.25%
2024-10-03SaleChief Accounting Officer
301
0.0003%
$0.81$245-2.25%
2024-08-20SaleChief Executive Officer
5,390
0.0046%
$0.74$3,996+2.67%

Insider Historical Profitability

<0.0001%
Brainard DianaChief Executive Officer
723363
0.6261%
$0.57134+5.55%
GILEAD SCIENCES, INC.10 percent owner
16635286
14.3982%
$0.5710<0.0001%
Jovan-Embiricos Moranadirector
342693
0.2966%
$0.5717+5.55%
VAN BEEK JEROEN BChief Commercial Officer
333726
0.2888%
$0.57134+5.55%
Atillasoy ErcemSee Remarks
131372
0.1137%
$0.5718+5.55%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Ecor1 Capital Llc$8.53M9.8211.29MNew+$8.53M0.06
Artal Group S A$4.98M5.746.6M0%+$00.02
Octagon Capital Advisors LP$3.17M3.654.2MNew+$3.17M0.02
BlackRock$2.56M2.943.39M-3.98%-$105,898.13<0.0001
Millennium Management LLC$2.22M2.562.94M-24.63%-$725,761.69<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.